Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a
company focused on developing, marketing, and selling a variety of
men’s health and wellness products via a secure telemedicine
platform, including its uniquely formulated hair growth product
branded ‘GROW’ and erectile dysfunction (ED) drug branded “Mango,”
today announced that it has selected TRYBE Labs to provide its
customers with a minimally invasive FDA approved at-home blood
collection device and testing services as the Company seeks to
further expand its product lines requiring blood tests and results
reviewed by physicians.
Using innovative, FDA approved at-home blood
collection technology, TRYBE Labs is a CLIA certified and Joint
Commission accredited laboratory that provides a direct-to-consumer
product which includes an easy-to-use collection kit, full range of
testing, and physician-read results for male health and performance
evaluation - including hormone, thyroid and vitamin levels.
“As we have been continuously working to bring
additional pharmaceutical based products and solutions to market,
the requirement for our physicians to review up-to-date blood work
and results has become paramount,” said Jacob Cohen, MangoRx’s
co-founder and CEO. “TRYBE Labs offers a unique, innovative,
convenient, and minimally invasive approach for blood collection
and testing along with fast result turnaround times (in as little
as 72 hours) for patients across the United States. What makes our
partnership that much greater is that TRYBE Labs and MangoRx are
completely aligned with our respective approaches in being
disruptive in our industries and we are thrilled to work with them
and their team on this endeavor.”
TRYBE Labs will also be joining the Company as
one of their affiliate marketing partners to further create
awareness and drive sales of MangoRx’s men’s health and wellness
related products through its own direct-to-consumer marketing
efforts.
“TRYBE Labs was built by men, for men,” said
Lewis Scalione, Founding Partner, TRYBE Labs. “We know many men are
hesitant to seek medical care and that they may struggle with the
perceived stigma that comes with low energy or suboptimal
performance - at the gym or in the intimate moments of their lives.
By putting the power of information and cutting-edge technology
directly into their hands, we are making healthcare more accessible
to all who need it.”
About MangoRxMangoRx is focused
on developing a variety of men's health and wellness products and
services via a secure telemedicine platform. To date, the Company
has identified men's wellness telemedicine services and products as
a growing sector and especially related to the area of erectile
dysfunction (ED) and hair growth. Interested consumers can use
MangoRx’s telemedicine platform for a smooth medical prescription
that is exclusively compounded for each individual. Orders will
then be reviewed by a physician and, if approved, fulfilled and
discreetly shipped through MangoRx’s partner compounding pharmacy
and right to the patient’s doorstep. To learn more about MangoRx’s
mission and other products, please visit www.MangoRx.com or on
social media @Mango.Rx.
About TRYBE LabsTRYBE Labs is
the only FDA-approved, at-home collection and testing service on
the market today that is designed specifically for men. With an
interactive online portal for monitoring, scoring and tracking of
results, TRYBE Labs is delivering the future of men’s health
today. Visit trybelabs.us.
Cautionary Note Regarding Forward-Looking
Statements
Certain statements made in this press release
contain forward-looking information within the meaning of
applicable securities laws, including within the meaning of the
Private Securities Litigation Reform Act of 1995 ("forward-looking
statements"). These forward-looking statements represent the
Company's current expectations or beliefs concerning future events
and can generally be identified using statements that include words
such as "estimate," "expects," "project," "believe," "anticipate,"
"intend," "plan," "foresee," "forecast," "likely," "will," "target"
or similar words or phrases. These forward-looking statements are
subject to risks, uncertainties and other factors, many of which
are outside of the Company's control which could cause actual
results to differ materially from the results expressed or implied
in the forward-looking statements, including, but not limited to;
our ability to obtain additional funding and generate revenues to
support our operations; risks associated with our ED product which
have not been, and will not be, approved by the U.S. Food and Drug
Administration ("FDA") and have not had the benefit of the FDA's
clinical trial protocol which seeks to prevent the possibility of
serious patient injury and death; risks that the FDA may determine
that the compounding of our planned products does not fall within
the exemption from the Federal Food, Drug, and Cosmetic Act ("FFDCA
Act") provided by Section 503A; risks associated with related party
relationships and agreements; the effect of data security breaches,
malicious code and/or hackers; competition and our ability to
create a well-known brand name; changes in consumer tastes and
preferences; material changes and/or terminations of our
relationships with key parties; significant product returns from
customers, product liability, recalls and litigation associated
with tainted products or products found to cause health issues; our
ability to innovate, expand our offerings and compete against
competitors which may have greater resources; our significant
reliance on related party transactions; the projected size of the
potential market for our technologies and products; risks related
to the fact that our Chairman and Chief Executive Officer, Jacob D.
Cohen and President, Jonathan Arango, combined have majority voting
control over the Company; risks related to the significant number
of shares in the public float, our share volume, the effect of
sales of a significant number of shares in the marketplace, and the
fact that the majority of our shareholders paid less for their
shares than the public offering price of our common stock in our
recent initial public offering; the fact that we have a significant
number of outstanding warrants to purchase shares of common stock
at $1.00 per share, the resale of which underlying shares have been
registered under the Securities Act of 1933, as amended; our
ability to build and maintain our brand; cybersecurity, information
systems and fraud risks and problems with our websites; changes in,
and our compliance with, rules and regulations affecting our
operations, sales, marketing and/or our products; shipping,
production or manufacturing delays; regulations we are required to
comply with in connection with our operations, manufacturing,
labeling and shipping; our dependency on third-parties to prescribe
and compound our ED product; our ability to establish or maintain
relations and/or relationships with third-parties; potential safety
risks associated with our Mango ED product, including the use of
ingredients, combination of such ingredients and the dosages
thereof; the effects of high inflation, increasing interest rates
and economic downturns, including potential recessions, as well as
macroeconomic, geopolitical, health and industry trends, pandemics,
acts of war (including the ongoing Ukraine/Russian conflict) and
other large-scale crises; our ability to protect intellectual
property rights; our ability to attract and retain key personnel to
manage our business effectively; our ability to maintain the
listing of our common stock on the Nasdaq Capital Market; overhang
which may reduce the value of our common stock; volatility in the
trading price of our common stock; and general consumer sentiment
and economic conditions that may affect levels of discretionary
customer purchases of the Company's products, including potential
recessions and global economic slowdowns. Although we believe that
our plans, intentions and expectations reflected in or suggested by
the forward-looking statements we make in this release are
reasonable, we provide no assurance that these plans, intentions or
expectations will be achieved. Consequently, you should not
consider any such list to be a complete set of all potential risks
and uncertainties.
More information on potential factors that could
affect the Company's financial results is included from time to
time in the "Cautionary Note Regarding Forward-Looking Statements,"
"Risk Factors" and "Management's Discussion and Analysis of
Financial Condition and Results of Operations" sections of the
Company's filings with the SEC, including the Company’s Quarterly
Report on Form 10-Q for the Quarter ended September 30, 2023. These
filings are available at www.sec.gov and at our website at
https://www.mangoceuticals.com/sec-filings. All subsequent written
and oral forward-looking statements attributable to the Company or
any person acting on behalf of the Company are expressly qualified
in their entirety by the cautionary statements referenced above.
Other unknown or unpredictable factors also could have material
adverse effects on the Company's future results. The
forward-looking statements included in this press release are made
only as of the date hereof. The Company cannot guarantee future
results, levels of activity, performance or achievements.
Accordingly, you should not place undue reliance on these
forward-looking statements. Finally, the Company undertakes no
obligation to update these statements after the date of this
release, except as required by law, and takes no obligation to
update or correct information prepared by third parties that are
not paid for by the Company. If we update one or more
forward-looking statements, no inference should be drawn that we
will make additional updates with respect to those or other
forward-looking statements.
Follow Mangoceuticals and MangoRx on social
media: https://www.instagram.com/mango.rx
https://twitter.com/Mangoceuticals
https://www.facebook.com/MangoRxOfficial
FOR PUBLIC RELATIONS Lucky Break Public
Relations Sahra Simpson Sahra@luckybreakpr.com (323) 602-0091 ext.
704
FOR INVESTOR RELATIONS Mangoceuticals Investor
Relations Email: investors@mangorx.com
MEDIA CONTACT PHOENIX MGMT Marketing &
Consulting info@phoenix-mediamarketing.com
SOURCE: Mangoceuticals Inc.
Mangoceuticals (NASDAQ:MGRX)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Mangoceuticals (NASDAQ:MGRX)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024